Stability of Essential Drugs in Tropical Climates: Zimbabwe - EDM Research Series No. 013
(1994; 86 pages) Voir le document au format PDF
Table des matières
Afficher le documentAbbreviations
Afficher le document1. Summary
Ouvrir ce répertoire et afficher son contenu2. Introduction
Ouvrir ce répertoire et afficher son contenu3. Study design and methods
Afficher le document4. Results
Ouvrir ce répertoire et afficher son contenu5. Discussion
Ouvrir ce répertoire et afficher son contenu6. Conclusions and recommendations
Afficher le documentReferences
Fermer ce répertoireAnnexes
Fermer ce répertoireAnnex 1: Detailed results for each drug
Afficher le document1.1 Amoxycillin capsules
Afficher le document1.2 Ampicillin capsules
Afficher le document1.3 Acetylsalicylic acid tablets
Afficher le document1.4 Doxycycline capsules
Afficher le document1.5 Ferrous sulfate tablets
Afficher le document1.6 Phenoxymethylpenicillin tablets
Afficher le document1.7 Tetracycline capsules
Afficher le document1.8 Retinol tablets
Afficher le document1.9 Epinephrine injection
Afficher le document1.10 Ampicillin injection
Afficher le document1.11 Benzylpenicillin injection
Afficher le document1.12 Ergometrine injection
Afficher le document1.13 Procaine penicillin injection
Afficher le documentAnnex 2: Validation of laboratory results
 

1.4 Doxycycline capsules

SHELF LIFE

Manufacturer A: 2-3 years

ASSAY METHOD

In-house HPLC method Contents of 20 capsules mixed; measured three times; mean taken.

ASSAY LIMITS

90 - 120% (USP)

SAMPLES OBTAINED

Manufacturer A

GMS samples

no.

%

Total

5

100

Harare

2

40

Bulawayo

3

60

Facility samples

no.

%

Total

15

100

Age > 50% SLife

9

60

Facility type = PCH

0

0

Climate = hot

3

20

Transport = slow

10

67

Longitudinal series

   

Total

5

100

SUMMARY ASSAY RESULTS

GMS samples

Manufacturer A

Mean age (mths)

 

8.9

Mean assay

 

102.1%

95% CL

96.6 - 107.7%

No, and % fail

0

0%

Facility samples

Manufacturer A

Mean age (mths)

 

17.3

Mean assay

 

110.1%

95% CL

105.0 - 115.1%

No, and % fail

2

13%

No, and % low fail

1

7%

No, and % high fail

1

7%

Longitudinal series

at manufacturer

at GMS

at facility

Mean age (mths)

 

0

6.9

17.1

Mean assay

 

100.4%

104.9%

109.8%

95% CL

98.6 - 102.1 %

99.6-110.2%

106.1 - 113.5%

No. and % fail

0

0%

0

0%

0

0%

 

Mean interval (mths)

10.1

 

Mean loss (-) or gain (+)

+5.0%

 

95% CL for loss/gain

-2.0 to +11.9%


Figure 1 - Results of facility samples

Findings:

a) Five of 20 facility samples (26%) were expired; these results were excluded.

b) All five GMS samples were within assay limits (mean 102.1 %).

c) Two of 15 facility samples (13%) failed; one failure was below the lower limit (82.7%) at age 21.9 months.

One failure was above the upper limit (125.2%).

The mean facility assay tended towards the upper limit of specifications (110.1%),

d) No consistent loss of potency was found in five GMS/facility sample pairs.

e) Small sample size/wide confidence limits make interpretation difficult,

f) No initial quality problem was seen.

g) No evidence of instability, except one failure which may be due to a measurement error,

h) Three expired samples had a lower mean assay (97.8%) at mean age 27.7 months.

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 3 mai 2013